Breaking Finance News

Aegis issued a report on Revance Therapeutics (NDAQ:RVNC), stepping up its target to $36.00 earlier today

Boasting a price of $24.88, Revance Therapeutics (NDAQ:RVNC) traded -0.37% lower on the day. With the last stock price close up 14.28% from the two hundred day average, compared with the S&P 500 Index which has increased 0.03% over the date range. Revance Therapeutics has recorded a 50-day average of $25.38 and a two hundred day average of $23.41. Volume of trade was down over the average, with 1,261 shares of RVNC changing hands under the typical 159,772

Aegis bumped up the target of Revance Therapeutics (NDAQ:RVNC) to $36.00 stating a potential upside of 0.45%.

On 05/02/2017, Aegis released a statement for Revance Therapeutics (NDAQ:RVNC) bumped up the target price from $0.00 to $28.00 that suggested an upside of 0.37%.

Performance Chart

Revance Therapeutics (NDAQ:RVNC)

With a total market value of $0, Revance Therapeutics has with a one year low of $12.35 and a one year high of $28.75 .

In addition to Aegis reporting its target price, a total of 6 firms have reported on the stock. The consensus target price is $51.33 with 3 firms rating the stock a strong buy, 2 firms rating the stock a buy, 0 firms rating the stock a hold, 0 firms rating the stock a underperform, and finally 0 firms rating the stock a sell.

About Revance Therapeutics (NDAQ:RVNC)

Revance Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on the development, manufacturing and commercialization of botulinum toxin products for multiple aesthetic and therapeutic indications. Its peptide technology enables delivery of botulinum toxin type A through two investigational drug product candidates, DaxibotulinumtoxinA for Injection (RT002), or RT002 injectable, and DaxibotulinumtoxinA Topical Gel (RT001), or RT001 topical. It is engaged in the clinical development for RT002 injectable. RT002 injectable utilizes botulinum toxin-peptide complex in a saline-based formulation. In RT002 injectable, the peptide interacts with both extracellular structures and cell surface receptors in the targeted muscle. This interaction restricts the toxin molecule to the target site and reduces unwanted spread to other neighboring muscles. It is focusing on developing RT002 for the treatment of glabellar lines, cervical dystonia and plantar fasciitis.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.